Having revolutionised the obesity treatment landscape, GLP-1 receptor agonists are now showing promise in Alzheimer’s disease, with their apparent neuroprotective effects able to reduce cognitive decline.
https://firstwordpharma.com/story/5880297
New research suggests that Novo Nordisk’s GLP-1 agonist liraglutide can protect the brains of people with mild Alzheimer’s disease, slowing cognitive decline by as much as 18% after one year of treatment versus placebo. The Phase IIb study findings were reported Tuesday at the Alzheimer’s Association International Conference (AAIC).
https://firstwordpharma.com/story/5880297
New research suggests that Novo Nordisk’s GLP-1 agonist liraglutide can protect the brains of people with mild Alzheimer’s disease, slowing cognitive decline by as much as 18% after one year of treatment versus placebo. The Phase IIb study findings were reported Tuesday at the Alzheimer’s Association International Conference (AAIC).